Charles Explorer logo
🇬🇧

Vildagliptin nezvyšuje kardiovaskulární riziko diabetiků 2. typu

Publication at Second Faculty of Medicine |
2018

This text is not available in the current language. Showing version "cs".Abstract

Souhrn s komentářem. Citace: Williams R, de Vries F., Kothny W, et al.

Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study. Diabetes Obes Metab. 2017 Oct;19(10): 1473-1478.